Vertex Pharmaceuticals in the NEWS

On November 8, 2025, Vertex Pharmaceuticals Incorporated (VRTX) announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology Kidney Week 2025 in Houston, Texas.

Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the . . .